Back to News
Market Impact: 0.35
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
Source: marketbeat.com
Healthcare & BiotechProduct Launches
The FDA approved Teva’s WELTRUZA, a once-monthly, long-acting injectable formulation of olanzapine for schizophrenia. The approval is a positive product milestone for Teva; the article provides no sales outlook or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
TEVA0.75
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- Stocks making the biggest moves midday: T-Mobile, Verizon, AT&T, Crown Castle, Teva & more
- J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
- Tesla’s ‘Full Self-Driving’ Becomes ‘Assisted Driving’ in Europe
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- Cramer: Investors selling Apple on latest iPhone 18 report are 'stupid as plywood'